Mustafa Prize laureate introduces COVID19 diagnostic kit

0 Dec 05 2020 In بین‌المللی

Addressing the 5th Exposure of Industries to Scientists’ Achievements Summit (EISA), Former Mustafa Prize laureate Jackie Ying elaborated on TEPAT 1.0 Multiplex RT-PCR KIT.


Ying discussed about Cellbae Pte Ltd, an innovative in-vitro diagnostics company headquartered in Singapore.


It spun off from the Agency for Science, Technology and Research (A*STAR) in 2017, launching in-vitro drug toxicity research products worldwide.


"TEPAT 1.0 can detect 6 copies of viral RNA per reaction with more than 95 percent confidence,” Ying said.

"It has one of the best, if not the best, Limit of Detection in the market right now. It is the only kit in the market that has 100 percent coverage with 100% identity of all SARS-CoV-2 genomes in the world,” she added.

"Clinical validation shows 100% sensitivity, with no cross-reaction with non-SARS-CoV-2 species,” she noted.

"These genes are exposed to different selective pressure and as such even if the virus mutates, Cellbae’s test should be able to detect these new variants through the detection of at least one of the viral targets,” Ying said.

In addition, Cellbae has developed TEPAT 2.0 Direct RT-PCR with nasal swab sample, which according to Ying, is currently under review by the Health Sciences Authority of Singapore and expects approval within two weeks.


Ying introduced some additional products developed by Cellabe under the categories of Cellbae Product Pipeline 1, Cellbae Product Pipeline 2, and Cellbae Product Pipeline 3. These include Real Time RT-PCR Assays, Nanoprobe assays, and Seroflow Paper-based Rapid Test Kits.

She went on to say that Cellbae is developing global reach, looking for distributors, strategic partners and clinical collaborators in the Middle East, South America, Eastern Europe, and North Asia. The company has so far appointed distributors in Nigeria, some countries from Western Europe, and Asia Pacific.

Edited On : Jan 02 2021

No Comments.